Combination therapy of carbon dioxide laser with topical halometason cream and 308 nm excimer laser for the treatment of vitiligo: an optimized combined treatment protocol.
Yi Yang, Molu Ozukum, Weiyi Zou et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated fractional CO₂ laser plus topical halometasone cream and 308-nm excimer lamp therapy for refractory non-segmental vitiligo, compared with excimer therapy, a topical calcineurin inhibitor, and halometasone without laser. The trial included 98 patients with 158 lesions: 60 phototherapy platform-stage (PPV) and 98 acral (AV) lesions. After three months, successful outcomes occurred in 50% of treated PPV lesions versus 10% of control PPV lesions (P ≤ 0.000). For AV lesions, success rates were 8.16% and 6.12%, respectively (P = 0.425).
Key findings
- For PPV lesions, success was reported in 50% with triple therapy versus 10% with control treatment (P ≤ 0.000).
- For AV lesions, success was 8.16% with triple therapy and 6.12% with control treatment (P = 0.425).
- Testing on 64 human foreskin samples identified 15 mJ pulse energy and 10% coverage as settings associated with more widespread, consistent topical distribution and minimal side effects.
Why it matters
The findings suggest that adding fractional CO₂ laser to topical halometasone and excimer therapy may improve outcomes for phototherapy platform-stage lesions, while offering little demonstrated benefit for acral lesions. The differing results by lesion location underscore the importance of interpreting treatment response by vitiligo subtype rather than assuming a combined approach works uniformly.
What to keep in mind
The clinical trial followed treatment for three months; the abstract does not report longer-term outcomes.